ASTROTECH earnings release, May 13, 2026

ASTROTECH Corp (ASTC) · Form 8-K, Item 2.02 · Filed · SEC filing

Astrotech Reports Third Quarter of Fiscal Year 2026 Financial Results

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the third quarter of fiscal year 2026, which ended March 31, 2026.

Financial Hi g hlights & Recent Developments

“During the third quarter of fiscal year 2026, we remained focused on disciplined execution, achieving targeted cost-efficiency initiatives while continuing to invest selectively in the highest-return areas of the business. As a result, we are better positioned to operate efficiently in a dynamic macro environment. At the same time, our sales team is advancing a healthy sales pipeline supported by strong lead generation and ongoing customer engagement across key markets. Our deployments to date support these efforts with real-world demonstration of our solution capabilities and compelling data affirming the unique benefits of mass spectrometry technology in industrial, safety and trace detection applications. Looking ahead, we will continue to balance rigorous expense control with strategic investments to help convert pipeline opportunities into revenue growth”, said Thomas B. Pickens, III, Astrotech’s Chairman and Chief Executive Officer.

About Astrotech Corporation

Astrotech Corporation (Nasdaq: ASTC) is an instrumentation company that creates, operates, and scales innovative businesses through its wholly owned subsidiaries. Each subsidiary leverages Astrotech’s core technology to serve specialized markets:

Astrotech is headquartered in Austin, Texas. For more information, visit www.astrotechcorp.com

Financial statements

Income Statement

Three Months Ended — (Unaudited) (in thousands)

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025Nine Months Ended – March 31, – 2026Nine Months Ended – March 31, – 2025
Revenue343534787829
Cost of revenue276297525428
Gross profit67237262401
Operating expenses:Selling, general and administrative2,0852,1155,9415,842
Operating expenses:Research and development1,4351,9895,2116,375
Operating expenses:Total operating expenses3,5204,10411,15212,217
Operating expenses:Loss from operations-3,453-3,867-10,890-11,816
Operating expenses:Other income and expense, net-315234-271896
Operating expenses:Loss from operations before income taxes-3,768-3,633-11,161-10,920
Operating expenses:Net loss-3,768-3,633-11,161-10,920
Weighted average common shares outstanding:Basic and diluted1,6771,6651,6761,663
Basic and diluted net loss per common share:Net loss per common share-2.25-2.18-6.66-6.57
Other comprehensive loss, net of tax:Net loss-3,768-3,633-11,161-10,920
Available-for-sale securities:Net unrealized gain (loss)159139476236
Available-for-sale securities:Total comprehensive loss-3,609-3,494-10,685-10,684

Balance Sheet

(In thousands, except share and per share data)

March 31, – 2026 – (Unaudited)June 30, – 2025 – (Note)
Current assetsCash and cash equivalents2,6793,100
Current assetsShort-term investments3,90315,108
Current assetsAccounts receivable504485
Inventory, net:Raw materials3,0192,194
Inventory, net:Work-in-process531425
Inventory, net:Finished goods310310
Inventory, net:Prepaid expenses and other current assets383353
Inventory, net:Total current assets11,32921,975
Inventory, net:Property and equipment, net2,5732,395
Inventory, net:Intangible asset, net5048
Inventory, net:Operating lease right-of-use assets, net1,9062,225
Inventory, net:Other assets, net315346
Inventory, net:Total assets16,17326,989
Current liabilitiesAccounts payable2341,066
Current liabilitiesPayroll related accruals461529
Current liabilitiesAccrued expenses and other liabilities865451
Current liabilitiesLease liabilities, current275405
Current liabilitiesTotal current liabilities1,8352,451
Current liabilitiesAccrued expenses and other liabilities, net of current portion79164
Current liabilitiesLease liabilities, net of current portion2,1042,274
Current liabilitiesTotal liabilities4,0184,889
Stockholders’ equityCommon stock, $0.001 par value, 250,000,000 shares authorized at March 31, 2026, and June 30, 2025, respectively; 1,769,269 shares issued at March 31, 2026, and June 30, 2025 respectively; 1,758,953 shares outstanding at March 31, 2026, and June 30, 2025.190,643190,643
Stockholders’ equityTreasury shares, 10,316 at March 31, 2026, and June 30, 2025, respectively-119-119
Stockholders’ equityAdditional paid-in capital84,05083,310
Stockholders’ equityAccumulated deficit-262,030-250,870
Stockholders’ equityAccumulated other comprehensive loss-389-864
Stockholders’ equityTotal stockholders’ equity12,15522,100
Stockholders’ equityTotal liabilities and stockholders’ equity16,17326,989
Full release

Forward-Looking Statements

This press release contains “forward-looking statements” that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These factors include, but are not limited to, the adverse impact of inflationary pressures, including significant increases in fuel costs, global economic conditions and events related to these conditions, including the ongoing wars in Ukraine and the middle east, the Company’s use of proceeds from the common stock offerings, whether we can successfully complete the development of our new products and proprietary technologies, whether we can obtain the FDA and other regulatory approvals required to market our products under development in the United States or abroad, whether the market will accept our products and services and whether we are successful in identifying, completing and integrating acquisitions, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements in this document should be evaluated in light of these important risk factors. While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others mentioned herein. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Moreover, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. In addition, any forward- looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to correct or update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Company Contact:

Scott Bartley

Interim Chief Financial Officer, Astrotech Corporation

(512) 485-9530

Investor Contact:

Matt Kreps

Managing Director, Darrow Associates

(214) 597-8200 mkreps@darrowir.com

Financial tables follow

ASTROTECH CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data)

(Unaudited)

ASTROTECH CORPORATION AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

Note: The balance sheet at June 30, 2025 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by the United States generally accepted accounting principles for complete financial statements.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · ASTROTECH earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.